Account
Watchlists
Bookmarks
Pricing
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2025
CORONA Remedies Limited is an India-focused pharmaceutical company specializing in branded formulations across key therapeutic areas including women's healthcare, cardio-diabeto, pain management, and urology. The company has demonstrated rapid growth, outpacing the Indian Pharmaceutical Market (IPM) through a diversified portfolio of over 71 brands with a strategic focus on the chronic and sub-chronic segments. Its marketing strategy targets specialist doctors in urban and semi-urban centers, supported by a pan-India sales network and two WHO-GMP certified manufacturing facilities. CORONA Remedies also focuses on strategic brand acquisitions and in-licensing to complement its robust R&D capabilities and expand its market presence.
Dec 08, 2025
Dec 10, 2025
Dec 15, 2025
Mainboard
Closed
655.37 Cr
0 Cr
655.37 Cr
₹1008 - ₹1062
14
The objectives of the Offer are to carry out the Offer for Sale of Equity Shares by the Selling Shareholders and to achieve the benefits of listing the Equity Shares on the Stock Exchanges.
To provide an opportunity for the Selling Shareholders to sell their Equity Shares and realize the benefits of their investment.
To enhance the company's brand name and create a public market for the Equity Shares in India, thereby providing liquidity to the existing shareholders.
43.47
24.43
27.5%
41.32%
24.65%
—
12.49%
20.55%
10.71
Second fastest-growing among the top 30 pharma companies in India, with domestic sales growth 1.82 times the IPM's growth between MAT June 2022-2025.
Diversified and strong portfolio of brands, with 27 'engine' brands contributing to over 72% of domestic sales.
Pan-India sales network with a differentiated marketing strategy targeting specialist doctors in the 'middle of the pyramid'.
Quality-focused manufacturing with EU GMP and WHO GMP certified facilities and strong R&D capabilities.
Significant dependence on third-party manufacturers for finished products, accounting for about 36% of revenue in FY2025.
Revenue concentration in the therapeutic areas of women's healthcare, cardio-diabeto, and pain management, which together contributed over 62% of revenue in FY2025.
Exposure to supply chain risks due to dependence on imports from China for about 70% of intermediaries for APIs.
Operates in a highly fragmented and competitive domestic pharmaceutical industry.
The Indian domestic formulation market is projected to grow at a strong CAGR of 8-9% between FY2025 and FY2030.
Increasing prevalence of chronic and lifestyle-related diseases in India is expected to drive demand for the company's focused therapeutic areas.
Opportunity to expand into new high-growth therapeutic areas like nephrology, central nervous system, and dermatology.
Potential to expand sales in select overseas markets by leveraging hormone product portfolio and international certifications.
Operates in a highly regulated industry, with risks from regulatory changes, including drug price controls under the DPCO.
Intense competition from a large number of domestic and multinational pharmaceutical companies.
Vulnerability to exchange rate fluctuations, which can impact costs of imported raw materials and export earnings.
Risk of regulatory actions, such as bans on certain fixed-dose combination (FDC) drugs, which could impact the product portfolio.